| 词条 | List of selective estrogen receptor modulators |
| 释义 |
This is a list of selective estrogen receptor modulators (SERMs). ApprovedSERMs that have been approved for medical use include anordrin (+mifepristone (Zi Yun)), bazedoxifene (+conjugated estrogens (Duavee)), broparestrol (Acnestrol), clomifene (Clomid), cyclofenil (Sexovid), lasofoxifene (Fablyn), ormeloxifene (Centron, Novex, Novex-DS, Sevista), ospemifene (Osphena; deaminohydroxytoremifene), raloxifene (Evista), tamoxifen (Nolvadex), and toremifene (Fareston; 4-chlorotamoxifen).[1] Clinical trialsSERMs that are currently under development and in clinical trials include acolbifene, afimoxifene (4-hydroxytamoxifen; metabolite of tamoxifen), elacestrant, enclomifene ((E)-clomifene), endoxifen (4-hydroxy-N-desmethyltamoxifen; metabolite of tamoxifen), and zuclomifene ((Z)-clomifene).[2] Non-approvedSERMs that have not been approved for medical use include arzoxifene, brilanestrant, clomifenoxide (clomiphene N-oxide; metabolite of clomifene),[3] droloxifene (3-hydroxytamoxifen), etacstil, fispemifene, GW-7604 (4-hydroxyetacstil; metabolite of etacstil), idoxifene (pyrrolidino-4-iodotamoxifen), levormeloxifene ((L)-ormeloxifene), miproxifene, nafoxidine, nitromifene (CI-628), NNC 45-0095, panomifene, pipendoxifene (ERA-923), trioxifene, and zindoxifene (D-16726).[4][1][5][6][7] Sivifene (A-007) was initially thought to be a SERM due to its structural similarity to tamoxifen but it was subsequently found not to bind to the estrogen receptor (ER).[8] Tesmilifene (DPPE; YMB-1002, BMS-217380-01) is also structurally related to tamoxifen but similarly does not bind to the ER and is not a SERM.[9][10]StructureSERMs can be variously classified structurally as triphenylethylenes (tamoxifen, clomifene, toremifene, droloxifene, idoxifene, ospemifene, fispemifene, afimoxifene, others), benzothiophenes (raloxifene, arzoxifene), indoles (bazedoxifene, zindoxifene, pipendoxifene), tetrahydronaphthalenes (lasofoxifene, nafoxidine), and benzopyrans (acolbifene, ormeloxifene, levormeloxifene).[11][12][13] References1. ^1 {{cite journal|last1=Pinkerton|first1=JoAnn V.|last2=Thomas|first2=Semara|title=Use of SERMs for treatment in postmenopausal women|journal=The Journal of Steroid Biochemistry and Molecular Biology|volume=142|year=2014|pages=142–154|issn=0960-0760|doi=10.1016/j.jsbmb.2013.12.011}} {{Estrogens and antiestrogens}}{{Estrogen receptor modulators}}{{genito-urinary-drug-stub}}{{antineoplastic-drug-stub}}2. ^http://adisinsight.springer.com/ 3. ^{{cite book|title=Analytical Profiles of Drug Substances and Excipients|url=https://books.google.com/books?id=kia7bq8EM9IC&pg=PA112|date=20 March 1998|publisher=Academic Press|isbn=978-0-08-086120-3|pages=112–113}} 4. ^{{cite | author = World Health Organization | title = The use of stems in the selection of International Nonproprietary Names (INN)for pharmaceutical substances | year = 2013 | url = http://www.who.int/medicines/services/inn/StemBook_2013_Final.pdf}} 5. ^{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3}} 6. ^{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA106|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1}} 7. ^{{cite journal|last1=Taylor|first1=Hugh S.|title=Designing the ideal selective estrogen receptor modulator-an achievable goal?|journal=Menopause|volume=16|issue=3|year=2009|pages=609–615|issn=1072-3714|doi=10.1097/gme.0b013e3181906fa3|pmc=3107842}} 8. ^{{cite journal|last1=Eilender|first1=David|last2=LoRusso|first2=Patricia|last3=Thomas|first3=Leonard|last4=McCormick|first4=Catherine|last5=Rodgers|first5=Andrew H.|last6=Hooper|first6=Catherine L.|last7=Tornyos|first7=Karl|last8=Krementz|first8=Edward T.|last9=Parker|first9=Steven|last10=Morgan|first10=Lee Roy|title=4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers|journal=Cancer Chemotherapy and Pharmacology|volume=57|issue=6|year=2005|pages=719–726|issn=0344-5704|doi=10.1007/s00280-005-0124-2}} 9. ^{{cite journal | vauthors = Brandes LJ | title = N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer | journal = Hum Exp Toxicol | volume = 27 | issue = 2 | pages = 143–7 | year = 2008 | pmid = 18480139 | doi = 10.1177/0960327108090751 | url = }} 10. ^{{cite journal | vauthors = Brandes LJ, Hermonat MW | title = A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomes | journal = Biochem. Biophys. Res. Commun. | volume = 123 | issue = 2 | pages = 724–8 | year = 1984 | pmid = 6548377 | doi = | url = }} 11. ^{{cite book|author1=John P. Bilezikian|author2=Lawrence G. Raisz|author3=T. John Martin|title=Principles of Bone Biology|url=https://books.google.com/books?id=LEDkfnAIjdkC&pg=PA891|date=29 September 2008|publisher=Academic Press|isbn=978-0-08-056875-1|pages=891–}} 12. ^{{cite book|author1=Stuart Silverman|author2=Bo Abrahamsen|title=The Duration and Safety of Osteoporosis Treatment: Anabolic and Antiresorptive Therapy|url=https://books.google.com/books?id=5bFPCwAAQBAJ&pg=PA24|date=29 December 2015|publisher=Springer|isbn=978-3-319-23639-1|pages=24–}} 13. ^{{cite book|author1=Atta-ur Rahman|author2=Khurshid Zaman|title=Topics in Anti-Cancer Research|url=https://books.google.com/books?id=G0dsDgAAQBAJ&pg=PA559|date=28 November 2014|publisher=Bentham Science Publishers|isbn=978-1-60805-908-9|pages=559–565}} 1 : Selective estrogen receptor modulators |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。